That’s because Kalydeco and its follow up Orkambi have only been of use to a subset of CF patients. But now the company is gaining real momentum, and its new drugs look set to bring it to a new ...
Kalydeco was initially approved in 2012 to treat patients aged over six with a single mutation of the cystic fibrosis transmembrane regulator (CFTR) gene - known as G551D - which affects around ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback